David Imagawa, MD
Surgery · Orange, CANPI 1467532630
Payments from drug & device makers
Across 181 payments — averaging $5563.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$845K
- Incyte Corporation$84K
- Beigene, Ltd.$37K
- Dilon Technologies, Inc.$11K
- Biom'up SA$9K
- Eisai Inc.$9K
- plus $13K from 23 others
What the payments were for
- Consulting fees$39,43271%
- Speaking & faculty fees$3,6707%
- Travel & lodging$6,48912%
- Food & beverage$6,00911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 48 | $844,703 |
| Incyte Corporation | 33 | $83,989 |
| Beigene, Ltd. | 5 | $36,541 |
| Dilon Technologies, Inc. | 13 | $10,553 |
| Biom'up SA | 14 | $9,480 |
| Eisai Inc. | 15 | $9,136 |
| Davol Inc. | 3 | $3,500 |
| Genentech USA, Inc. | 3 | $3,330 |
| BD | 1 | $1,800 |
| Johnson & Johnson | 8 | $829 |
| AbbVie | 3 | $391 |
| Dova Pharmaceuticals | 3 | $316 |
| Angiodynamics, Inc. | 5 | $289 |
| Intra-sana Laboratories | 1 | $250 |
| AstraZeneca | 3 | $235 |
| Galvanize Therapeutics, Inc | 2 | $226 |
| ABK Biomedical USA, Inc. | 1 | $193 |
| Biom'up France SAS | 1 | $158 |
| Medtronic | 4 | $150 |
| Boston Scientific | 2 | $140 |
| Sobi, Inc | 1 | $136 |
| Heron Therapeutics, Inc. | 1 | $114 |
| Mallinckrodt Hospital Products Inc. | 1 | $97 |
| Solventum Corporation | 3 | $97 |
| Exelixis Inc. | 1 | $94 |
| Gilead | 2 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $44 |
| Baxter Healthcare | 1 | $42 |
| Cook Medical LLC | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HemoBlast Bellows$10,581
- HEMOBLAST$9,104
- LENVIMA$8,943
- TECENTRIQ$3,297
- Creon$391
- DOPTELET$367
- Reltone 200 Mg$250
- Reltone 400 Mg$250
- ALIYA SYSTEM$226
- STRATAFIX$222
- Eye90 microspheres$193
- PDS$140
- IMFINZI$133
- VISTASEAL$120
- CINVANTI$114
- MONOCRYL$101
How this compares
$1,006,935 in reported general payments places this provider in the 95th percentile of 2,363 surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgery in Orange
- Andrew BarlebenOrange$249K
- Timothy ChuterSan Francisco$8.9M
- Peter StockSan Francisco$6.5M
- Santiago HorganSan Diego$2.8M
- Kenneth DeckLaguna Hills$2.4M
- Daniel RiskinSan Jose$2.2M
- Michael DemeureNewport Beach$1.7M
- Rock LiuHayward$1.6M
- David LouriePasadena$1.4M
- Andrea PakulaThousand Oaks$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.